German Court Finds ArthroVision’s Patent Not Infringed by Chondrometrics

MONTREAL, QUEBEC--(Marketwire - April 03, 2009) - ArthroVision Inc., a wholly-owned subsidiary of Horizon Sciences & Technologies Inc., announced today that the District Court of Munich, Germany, decided that Chondrometrics GmbH has not infringed on the German part of ArthroVision’s patent EP 1 230 561. The patent relates to evaluating disease progression by means of magnetic resonance imaging. The Court determined that Chondrometrics software would not make use of claims 1 and 11 of the patent.

ArthroVision plans to promptly appeal in full the not yet final District Court’s infringement decision. ArthroVision executive officers believe that the first instance judgment of the Munich District Court will be corrected on appeal. ArthroVision is committed to globally protecting its intellectual property.

About Horizon Sciences & Technologies and ArthroVision Inc.

Horizon Sciences & Technologies Inc., a Canadian biopharmaceutical company located in Montreal, Quebec, Canada, is involved, in collaboration with its partners, in the discovery and development of new and innovative technologies for the prevention, the diagnosis and the treatment of osteoarthritis. Its subsidiary, ArthroVision Inc., a Montreal, Quebec, based company, is engaged in the research and development of imaging technology to assess the effect of therapeutics in the treatment of osteoarthritis. ArthroVision has developed imaging systems that allow the precise measurement and quantification of cartilage from magnetic resonance images (MRIs) and the tracking of cartilage degradation over time. These technologies represent a breakthrough for osteoarthritis research. ArthroVision has extensive expertise in conducting clinical trials for the assessment of the efficacy of new drugs and compounds that aim at reducing the progression of osteoarthritis.

Forward-Looking Statements

This press release contains “forward looking information” (as defined in applicable Canadian securities legislation) that are based on expectations, estimates and projections as of the date of this press release. Often, but not always, such forward looking information can be identified by the use of forward looking words such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward looking information in this press release. Examples of such forward looking information in this press release include, but are not limited to, factors relating to the possible appeal of first instance judgment of the Munich District Court, which is subject to significant risks and uncertainties, including the possibility that Court of Appeal may not find in favour of ArthroVision Inc. Actual results are likely to differ, and may differ materially, from those expressed or implied by the forward looking information contained in this press release. There can be no assurance that forward looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward looking information.